Exosomes are nanoscale vesicles — tiny membrane parcels that cells release to carry signalling molecules to other cells. In aesthetics they are marketed as bottled regeneration. The honest physician's summary: genuinely interesting biology, early but growing clinical evidence, and a regulatory landscape where what's in the bottle varies enormously — which makes the source and the setting matter more than the word on the label.
WhatsApp Dr Sin Yong →Cells talk to each other by post: they package signalling molecules into membrane vesicles — exosomes — and release them to be picked up by neighbours, where the cargo changes behaviour. The aesthetic hypothesis is direct: harvest exosomes from regenerative cell cultures and deliver their pro-repair signals to ageing or healing skin. The systematic-review literature finds genuinely encouraging early signals — improvements in skin texture, healing support after procedures — alongside the honest caveats of a young field: small trials, varied products and protocols [1,2].
Where data is most consistent: exosomes as an adjunct after energy-based treatments — applied to freshly lasered or microneedled skin, where reviews report faster settling and skin-quality gains [1]. Where marketing outruns evidence: exosomes as a standalone anti-ageing transformation, claims of 'stem cell results without stem cells', and the quiet blurring between very different products — a characterised human-cell-derived preparation and a plant-extract vesicle are not the same biology wearing the same name [2]. The scoping literature on the commercial landscape is blunt about this heterogeneity: what is in the bottle varies enormously between brands.
In Singapore and most jurisdictions, exosome products are used topically — typically applied immediately after fractional laser or microneedling, when channels in the skin allow penetration — as part of the recovery-and-result protocol rather than as an injected therapy. In Dr Sin Yong's practice that is exactly the slot they occupy when used: post-procedure support after platforms like the Tetra Pro or RF microneedling, chosen product by product on characterisation, not label poetry. For injected regenerative support, the evidence currently favours established biologicals — polynucleotides — over exosome injection, which remains outside the approved lane in most markets.
Replace a lifting treatment — signalling molecules do not reposition tissue. Substitute for diagnosis — 'regeneration' aimed at an undiagnosed condition is expensive hope. Erase the difference between products — source, characterisation and handling decide whether a vial contains biology or storytelling. And justify any injection outside the regulated lane — the setting and the supervision are part of what you are paying for, or should be.
“Exosome is a biology word doing marketing work — the same label covers characterised human-cell science and plant-extract storytelling, and the bottle won't tell you which you bought.”
— Dr Sin Yong
Leave your name and mobile number and the clinic will contact you directly. No obligation.
Prefer a preliminary view first? You can also WhatsApp a photo of the area for Dr Sin Yong to review before you decide on a visit.
Early systematic reviews report genuine promise, especially as topical support after energy treatments. The field is young: small studies, varied products. 'Promising adjunct' is the honest current verdict.
Topical use after procedures has a reassuring reported profile in the review literature. The safety question is really a product question — source and characterisation vary enormously between brands.
In most jurisdictions including Singapore, exosome products are used topically, not injected — injectable regenerative support belongs to established, regulated biologicals like polynucleotides.
No — they share a name and a vesicle structure, not a biology. Human-cell-derived and plant-derived products carry entirely different cargo. Ask any clinic which they use and why.
On intact skin, penetration of large vesicles is questionable — the clinical logic favours post-procedure application when channels are open. As shelf skincare, the evidence is far thinner than the pricing.
Different molecules, different evidence maturity. Polynucleotides carry systematic-review-level injected evidence; exosomes are the promising newcomer in the topical-adjunct lane. They answer different questions.